QC-BT16

Drug Profile

QC-BT16

Alternative Names: BT 16; SK 0412

Latest Information Update: 21 Jul 2010

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Class Antihyperlipidaemics; Obesity therapies
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia; Metabolic syndrome

Most Recent Events

  • 21 Jul 2010 Discontinued - Phase-I for Hyperlipidaemia in Japan (unspecified route)
  • 15 Mar 2007 Phase-I clinical trials in Hyperlipidaemia in Japan (unspecified route)
  • 10 Feb 2005 QC-BT16 is available for licensing in Europe and the US (http://www.quarkbiotech.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top